INTANGIBLE ASSETS AND GOODWILL (Details 2) (USD $)
|
3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2013
|
Sep. 30, 2012
|
Sep. 30, 2013
|
Sep. 30, 2012
|
Sep. 30, 2013
Amortization and Impairments of Finite-lived Intangible Assets
Developed Markets
Non-recurring basis
Ezogabine Retigabine
|
Sep. 30, 2013
Amortization and Impairments of Finite-lived Intangible Assets
Developed Markets
Non-recurring basis
Discontinued OTC Skincare [Member]
|
Mar. 31, 2013
Amortization and Impairments of Finite-lived Intangible Assets
Developed Markets
Non-recurring basis
Opana
|
Sep. 30, 2013
In-process Research and Development Impairments and Other Charges
Developed Markets
Non-recurring basis
Ezogabine Retigabine
|
Sep. 30, 2013
U.S
Amortization and Impairments of Finite-lived Intangible Assets
Developed Markets
Non-recurring basis
Discontinued OTC Skincare [Member]
|
Sep. 30, 2013
Australia
Amortization and Impairments of Finite-lived Intangible Assets
Developed Markets
Non-recurring basis
Discontinued OTC Skincare [Member]
|
Sep. 30, 2013
Brazilian, Canadian, and Polish Markets [Member]
Amortization and Impairments of Finite-lived Intangible Assets
Developed Markets
Non-recurring basis
Discontinued OTC Skincare [Member]
|
Sep. 30, 2013
Brazilian, Canadian, and Polish Markets [Member]
Amortization and Impairments of Finite-lived Intangible Assets
Developed Markets
Non-recurring basis
Opana
|
Sep. 30, 2013
In Process Research and Development [Member]
In-process Research and Development Impairments and Other Charges
Non-recurring basis
Ezogabine Retigabine
|
Sep. 30, 2013
In Process Research and Development [Member]
In-process Research and Development Impairments and Other Charges
Non-recurring basis
Lacrisert
|
|||||
Intangible assets | ||||||||||||||||||
Impairment charges on intangible assets | $ 551,600,000 | $ 10,000,000 | $ 22,200,000 | $ 93,800,000 | $ 10,000,000 | $ 31,500,000 | $ 22,300,000 | $ 22,200,000 | $ 93,800,000 | $ 27,300,000 | ||||||||
Amortization expense related to intangible assets recorded as follows: | ||||||||||||||||||
Cost of goods sold | 0 | 0 | 0 | 2,557,000 | ||||||||||||||
Amortization and impairments of finite-lived intangible assets (see Note 10) | 910,248,000 | 218,187,000 | 1,540,021,000 | 629,400,000 | ||||||||||||||
Total amortization of intangible assets | 910,248,000 | 218,187,000 | 1,540,021,000 | 631,957,000 | ||||||||||||||
Estimated aggregate amortization expense | ||||||||||||||||||
2013 | 1,243,488,000 | [1] | 1,243,488,000 | [1] | ||||||||||||||
2014 | 1,365,817,000 | [1] | 1,365,817,000 | [1] | ||||||||||||||
2015 | 1,317,121,000 | [1] | 1,317,121,000 | [1] | ||||||||||||||
2016 | 1,230,973,000 | [1] | 1,230,973,000 | [1] | ||||||||||||||
2017 | $ 1,177,238,000 | [1] | $ 1,177,238,000 | [1] | ||||||||||||||
|